Case Report and Retrospective Review of Acanthamoeba Encephalitis and Chronic Lymphocytic Leukemia, United States.

Emerg Infect DisSep 1, 2026
Case ReportHematologyInfectious Diseases

Michele Persico, Julia C Haston, Erin Imada et al.

✦ AI-curated · Sources linked

Case in brief

A patient with chronic lymphocytic leukemia (CLL) presented with Acanthamoeba encephalitis. The case highlights the association between CLL and Acanthamoeba infections, noting that CLL is the most common underlying malignancy in such cases. The patient’s condition was managed effectively, leading to improved survival outcomes compared to those with other malignancies.

Diagnostic / clinical pearl

Clinicians should be aware that chronic lymphocytic leukemia is a significant risk factor for Acanthamoeba infections, which may present as encephalitis.

Why it matters

Understanding the association between CLL and Acanthamoeba infections can aid in early diagnosis and management, potentially improving patient outcomes.

Source

PubMed · PMID 42661277

Published in Emerg Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.